Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03025477
PHASE2

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Sponsor: Groupe Hospitalier Diaconesses Croix Saint-Simon

View on ClinicalTrials.gov

Summary

CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

Official title: Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2016-10

Completion Date

2032-10

Last Updated

2021-02-11

Healthy Volunteers

No

Interventions

DRUG

CC0 - Carboplatin (IV) - Paclitaxel (IV)

(6 cycles)

DRUG

CC0 - Cisplatin (IP) - Epirubicin (IV)

(6 cycles)

DRUG

CC>0 - Carboplatin (IV)- Paclitaxel (IV)

* carboplatin (IV) - paclitaxel (IV) (3 cycles) * Interval surgery * Carboplatin (IV) - paclitaxel (IV) (3 cycles)

DRUG

CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)

* Cisplatin (IV) - Epirubicin (IV) (3 cycles) * Interval surgery : * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles) * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)

Locations (7)

Centre Georges François Leclerc

Dijon, France

Institut Hospitalier Franco-Britannique

Levallois-Perret, France

Groupe Hospitalier Diaconesses Croix Saint Simon

Paris, France

Hôpital Saint Antoine

Paris, France

Hôpital Poissy Saint Germain

Poissy, France

CHU Poitiers

Poitiers, France

Centre Hospitalier Senlis

Senlis, France